Name	Benjamin J. Samelson-Jones
Current Position & Affiliation	Assistant Professor University of Pennsylvania, Associate Direction of In Vivo Gene Therapy at The Children's Hospital of Philadelphia
Country	USA
Major Field	Hemostasis, Gene Therapy

Educational Background

2001	AB	Amherst College (Physics)
2009	MD/PhD	Albert Einstein College of Medicine (Biophysics)
2012		Resident, Pediatrics, Children's National Medical Center
2015		Fellow, Pediatric Hematology and Oncology, Children's Hospital of Philadelphia

Professional Experience

2018-present Assistant Professor, Perelman School of Medicine at the University of Pennsylvania

Other Experience and Professional Memberships

Member, Translational Science Committee of American Society of Cell and Gene Therapy
Member, Working Group for Hemostasis and Thrombosis of American Society of Hematology
Member, Board of Directors of Hemostasis and Thrombosis Research Society
Member, Borad of Directions of Williams Syndrome Association
Member, Editorial Board of Journal of Hemostasis and Thrombosis

Main Scientific Publications

Rasko JEJ, Samelson-Jones BJ, George LA, Giermasz A, Ducore JM, Teitel JM, McGuinn CE, High KA, de Jong YP, Chhabra A, O'Brien A, Smith LM, Winburn I, Rupon J.: Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. N Engl J Med 392: 1508-1517, Apr 2025.

Lee K, Chau JQ, Suber YB, Sternberg AR, Pishko A, George LA, Bhoj V, Doshi BS, Samelson-Jones BJ.: Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab. Blood 144(11): 1230, Sept 2024.

Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR.: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 5(3): e128683, Jun 2019. PMCID: PMC6675543

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. : Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine 377(23): 2215-2227, Dec 2017.